<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2783">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393142</url>
  </required_header>
  <id_info>
    <org_study_id>IF20-00004</org_study_id>
    <nct_id>NCT04393142</nct_id>
  </id_info>
  <brief_title>Serologic Testing of Household Contacts of Confirmed Cases of COVID-19</brief_title>
  <official_title>Observational Trial Evaluating the Serologic Status of Household Contacts of Patients Diagnosed With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SARS-CoV-2 has now crossed the 1 million number of cases and tens of thousands of deaths.
      It´s R0 has been calculated between 2 and 5.7 solely based on clinical symptoms but it is
      estimated to likely be higher. Serologic evidence of infection has not been analyzed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transverse, observational and descriptive study involving household contacts of documented
      patients with COVID-19 infection: contacts will be invited to participate and a blood sample
      will be drowned: IgM and IgG qualitative and quantitative measurements will be performed.
      Demographic data regarding age, comorbidities, calculated time spent before and after the
      patients diagnosis, isolation practices etc.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Identify antibodies</measure>
    <time_frame>1 day</time_frame>
    <description>Identify the presence of IgM and IgG antibodies from intradomestic contacts of patients with Polymerase Chain Reaction for detected SARS-CoV-2 .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine antibody sensitivity</measure>
    <time_frame>1 day</time_frame>
    <description>Determine the sensitivity of IgM and IgG antibody detection by ELISA in direct eastern contacts of patients with PCR for detected SARS-CoV-2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgM determination</measure>
    <time_frame>1 day</time_frame>
    <description>Determine the presence of IgM antibodies by ELISA in direct eastern contacts of patients with detected SARS-CoV-2 PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG determination</measure>
    <time_frame>1 day</time_frame>
    <description>Determine the presence of IgG antibodies by ELISA in direct eastern contacts of patients with detected SARS-CoV-2 PCR.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Coronavirus Infection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be obtained by capillary puncture or venipuncture for rapid testing of
      antibodies against SARS-CoV-2 (IVD COVID-19 IgM/IgG test kit, Singclean).

      Samples will be stored in the laboratory, and discarded at the discretion of the researcher.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The intradomiciliary contacts of the patients with a detected SARS-CoV-2 PCR test
        (nasopharyngeal and / or oropharyngeal swab) performed at the Acute Respiratory Infection
        Diagnosis Unit between March 2020 and May 2020 will be located: will invite to participate
        in the study to record their clinical and demographic data and to take serological samples
        by venipuncture or fingerstick to perform rapid tests for antibodies against SARS-CoV-2
        (IVD COVID-19 IgM / IgG test kit, Singclean).

        Informed consent shall be obtained from each person for the collection of samples. The data
        collected will be captured in an electronic database in Excel.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Persons over 1 years of age.

          2. .Meet COVID-19 confirmed case intradomestic contact definition:

               1. Living in the same home as the patient with SARS-CoV-2 PCR test detected
                  (nasopharyngeal and/or oropharyngeal swab) performed in the Acute Respiratory
                  Infection Diagnostic Unit.

               2. Living in the same home as the patient with a PCR test for SARS-CoV-2
                  Indeterminate (nasopharyngeal and/or oropharyngeal swab) performed in the Acute
                  Respiratory Infection Diagnostic Unit and that the initial patient has positive
                  IgM/IgG serology for SARS-CoV-2.

          3. .Informed Consent.

        Exclusion Criteria:

          1. .Have fever, cough, pharyngeal pain or clinically have symptoms compatible with
             COVID-19 at the time of recruitment.

          2. .Autoimmune disease, cancer, neutropenia.

          3. .Under 1 years of age.

          4. .Patients who, in the investigator's opinion, should be excluded from the research
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Camacho-Ortiz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario &quot;Dr. Jose Eleuterio Gonzalez, UANL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edurdo Pérez Alba, MD</last_name>
    <phone>+52 8117998705</phone>
    <email>md.eduardo.perez@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaime Eugenio Espinosa Mora, MD</last_name>
    <phone>+52 8115999286</phone>
    <email>dr.jaime.espinosa88@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario José E. Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Camacho, PhD</last_name>
      <phone>044 81 1263 5696</phone>
      <email>acamacho_md@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Pérez Alba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Marina Nuzzolo Shihadeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaime Eugenio Espinosa Mora, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gloria Mayela Aguirre García, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adrian Camacho-Ortiz, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov</url>
    <description>&quot;About the Virus.&quot; World Health Organization, World Health Organization, 17 Apr. 2020</description>
  </link>
  <link>
    <url>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it</url>
    <description>&quot;Naming the Coronavirus Disease (COVID-19) and the Virus That Causes It.&quot; World Health Organization. World Health Organization. Accessed April 17, 2020.</description>
  </link>
  <link>
    <url>https://coronavirus.jhu.edu/map.html.</url>
    <description>Johns Hopkins Coronavirus Resource Center.&quot; Johns Hopkins Coronavirus Resource Center. Accessed April 17, 2020.</description>
  </link>
  <link>
    <url>https://www.who.int/es/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</url>
    <description>Alocución de apertura del Director General de la OMS en la rueda de prensa sobre la COVID-19 celebrada el 11 de marzo de 2020&quot;. Organización Mundial de la Salud. Organización Mundial de la Salud. Accedido el 17 de abril de 2020</description>
  </link>
  <link>
    <url>https://www.nejm.org/doi/full/10.1056/NEJMp2002125</url>
    <description>Lipsitch, Marc, J. Grein, Y. Zhang, N. van Doremalen, and Center for Communicable Disease Dynamics. &quot;Defining the Epidemiology of Covid-19 - Studies Needed: NEJM.&quot; New England Journal of Medicine, April 10, 2020</description>
  </link>
  <link>
    <url>https://www.cebm.net/covid-19/comparative-accuracy-of-oropharyngeal-and-nasopharyngeal-swabs-for-diagnosis-of-covid-19/.</url>
    <description>Comparative Accuracy of Oropharyngeal and Nasopharyngeal Swabs for Diagnosis of COVID-19.&quot; CEBM. Accessed April 17, 2020.</description>
  </link>
  <link>
    <url>https://www.coronavirus.gov/.</url>
    <description>12. Cdc. &quot;Coronavirus Disease 2019 (COVID-19).&quot; Centers for Disease Control and Prevention. Accessed April 17, 2020</description>
  </link>
  <reference>
    <citation>Maier HJ, Bickerton E, Britton P. Preface. Coronaviruses. Methods Mol Biol. 2015;1282:v.</citation>
    <PMID>25870870</PMID>
  </reference>
  <reference>
    <citation>Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0. Review.</citation>
    <PMID>32169119</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Patel A, Jernigan DB; 2019-nCoV CDC Response Team. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 7;69(5):140-146. doi: 10.15585/mmwr.mm6905e1. Erratum in: MMWR Morb Mortal Wkly Rep. 2020 Feb 14;69(6):173.</citation>
    <PMID>32027631</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>Dr. Adrian Camacho-Ortiz</investigator_full_name>
    <investigator_title>Head of the Infectious Disease Department</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>IgM/IgG antibodies</keyword>
  <keyword>Intradomestic contacts</keyword>
  <keyword>IgM/IgG serological tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

